Cytori Therapeutics, Inc. develops cell therapies based on autologous adipose-derived stem and regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. The advanced therapeutic application in the Company's clinical pipeline is for cardiovascular disease. The Company�s products include Celbrush, Puregraft, and Cytori LipoBank. The Celbrush is available in the 10 milliliter and 3 milliliter sizes and is used in conjunction with a Soft-Ject Syringe in the corresponding size. The Puregraft System is developed for autologous fat grafting and aesthetic body contouring. The Puregraft System is available in two sizes: 250 milliliter, which processes 50-250 milliliter of tissue, and 850 milliliter, which processes 200-850 milliliter of tissue. The Cytori LipoBank is a GTP-compliant cryopreservation system that offers a long-term storage option for viable adipose tissue after a single liposuction.